Denis Lacombe

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.

Elizabeth Eisenhauer, Denis Lacombe, Michael Weller, 2008, The Lancet. Oncology.

Targeted therapies in the treatment of advanced/metastatic NSCLC.

D. Lacombe, C. Gridelli, J. V. van Meerbeeck, 2009, European journal of cancer.

EORTC Elderly Task Force experts' opinion for the treatment of colon cancer in older patients.

D. Lacombe, E. Van Cutsem, G. Folprecht, 2010, Cancer treatment reviews.

Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group.

D. Lacombe, P. Bachmann, P. Fumoleau, 2003, European journal of cancer.

Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion

D. Lacombe, M. Tubiana-Hulin, C. Rose, 1999, British Journal of Cancer.

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.

R. Stupp, A. Brandes, T. Gorlia, 2008, The Lancet. Oncology.

The European Cancer Patient’s Bill of Rights, update and implementation 2016

J. Bergh, M. Piccart, C. la Vecchia, 2016, ESMO Open.